Stock Analysis

Spectral Medical Full Year 2022 Earnings: Beats Expectations

Source: Shutterstock

Spectral Medical (TSE:EDT) Full Year 2022 Results

Key Financial Results

  • Revenue: CA$1.67m (down 19% from FY 2021).
  • Net loss: CA$7.60m (loss narrowed by 14% from FY 2021).
  • CA$0.028 loss per share (improved from CA$0.035 loss in FY 2021).
TSX:EDT Earnings and Revenue Growth March 25th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Spectral Medical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 71% growth forecast for the Biotechs industry in Canada.

Performance of the Canadian Biotechs industry.

The company's shares are down 7.4% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Spectral Medical you should be aware of, and 2 of them are a bit concerning.

Valuation is complex, but we're helping make it simple.

Find out whether Spectral Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis